Vincasar PFS (generic: vincristine) has been use in combination with other medicines to treat the following cancers: non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, acute lymphoblastic leukemia (ALL), Wilms’ tumor (a form of pediatric kidney cancer), rhabdomyosarcoma, and neuroblastoma. It has also been used in the treatment of the following blood disorders: thrombotic thrombocytopenic purpura (TTP) and idiopathic thrombocytopenic purpura (ITP).
Vincasar PFS belongs to a group of drugs called vinca alkaloids. It works by preventing cancer cells from properly dividing.
This medication comes in an injectable form to be given directly into a vein (IV) by a healthcare provider. It is usually given once a week.
Common side effects of Vincasar PFS include hairloss, nausea, vomiting, and diarrhea.